The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema

Basit Öğe Kaydı
dc.contributor.authorGuzel, Huseyin
dc.contributor.authorBakbak, Berker
dc.contributor.authorKoylu, Mehmet Talay
dc.contributor.authorGonul, Saban
dc.contributor.authorOzturk, Banu
dc.contributor.authorGedik, Sansal
dc.date.accessioned2020-03-26T19:42:50Z
dc.date.available2020-03-26T19:42:50Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: To investigate the effect and safety of intravitreal injection (IVI) of bevacizumab and ranibizumab on corneal endothelial cell count and morphology in patients with diabetic macular edema.Materials and methods: A total of 60 eyes from 60 consecutive patients who received 0.5mg/0.05ml IVIs of bevacizumab (n=30, IVB group) or 1.25mg/0.05ml ranibizumab (n=30, IVR group) for three consecutive months were investigated prospectively. Specular microscopy was performed to evaluate endothelial cell count, the percentage of hexagonal cells (pleomorphism), and the coefficient of variation of the cell size (polymegathism); optical biometry was performed to evaluate central corneal thickness. Results before injection and 1 month after the first and third injections were compared.Results: The groups were matched for age (p=0.11) and gender (p=0.32). There was no significant difference in endothelial cell count (IVB group, p=0.66; IVR group, p=0.74), pleomorphism (IVB group, p=0.44; IVR group, p=0.88) and polymegathism (IVB group, p=0.21; IVR group, p=0.24) before injection or 1 month after the first and third injections. There was also no difference in central corneal thickness (IVB group, p=0.15; IVR group, p=0.58) before injection or 1 month after the first and third injections.Conclusion: Monthly 1.25mg/0.05ml IVIs of bevacizumab or 0.5mg/0.05ml of ranibizumab for three consecutive months in the treatment of diabetic macular edema does not affect corneal morphology and has no harmful effects on the endothelium.en_US
dc.identifier.doi10.3109/15569527.2016.1140177en_US
dc.identifier.endpage8en_US
dc.identifier.issn1556-9527en_US
dc.identifier.issn1556-9535en_US
dc.identifier.issue1en_US
dc.identifier.pmid26911396en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage5en_US
dc.identifier.urihttps://dx.doi.org/10.3109/15569527.2016.1140177
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35532
dc.identifier.volume36en_US
dc.identifier.wosWOS:000393946800002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofCUTANEOUS AND OCULAR TOXICOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectBevacizumaben_US
dc.subjectcorneal endothelial counten_US
dc.subjectdiabetic macular edemaen_US
dc.subjectranibizumaben_US
dc.subjectspecular microscopyen_US
dc.subjectvascular endothelial growth factoren_US
dc.titleThe effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu